Engineering biomimetic graphene nanodecoys camouflaged with the EGFR/HEK293 cell membrane for targeted capture of drug leads
BIOMATERIALS SCIENCE
Authors: Hu, Qi; Zhang, Xiaolin; Jia, Lanlan; Zhen, Xueyan; Pan, Xiaoyan; Xie, Xiaoyu; Wang, Sicen
Abstract
Advanced graphene (G)-based nanomaterials have risen as emerging stars for biomedical applications over the past decade due to their unique physicochemical properties. However, the preparation of G-based nanomaterials with satisfactory bioactivity to meet the growing demands of multitasking applications in biocomplexity systems remains a challenge. Herein, we presented a biomimetic route to modify graphene oxide (GO) using high expression epidermal growth factor receptor cell membrane (CM). Owing to the inherent properties of the CM for multifaceted interaction with active ligands, the well camouflaged GO could capture the drug leads with targeting properties. The as-prepared CM-coated magnetic GO exhibited excellent binding properties, including good selectivity, high adsorption capacity, and suitable adsorption rates. In addition, by coupling this assay with mass spectrometry, two potential bioactive compounds, luteolin and caffeic acid, were screened fromTaraxacum mongolicum Hand.-Mazz.It is anticipated that this biomimetic approach can open new possibilities for the rational design of improved G-based biocomposites and extend their bioapplications.
Integration of biomonitoring data and reverse dosimetry modeling to assess population risks of arsenic-induced chronic kidney disease and urinary cancer
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
Authors: Lin, Yi-Jun; Hsiao, Ju-Ling; Hsu, Hui-Tsung
Abstract
Chronic exposure to inorganic arsenic (iAs) is associated with chronic kidney disease (CKD) and urinary cancer, but the risks are poorly understood. Human biomonitoring can serve as a tool to better quantify human exposure and to conduct risk assessment. We aimed to assess the population risks of CKD and urinary cancer due to iAs intake based on the blood arsenic concentrations of 601 participants in Taiwan. A physiologically based pharmacokinetic modeling-based reverse dosimetry was conducted to estimate the daily intakes of iAs (Db(iAs)). We performed the benchmark dose (BMD) modeling for CKD using participants' estimated glomerular filtration rate (eGFR) and the estimated DIiAs to derive a point of departure (POD). Margin of exposure (MOE) was used to characterize the risks. The population with eGFR values of <60 mL/min/1.73 m(2) had significantly higher DL A , (median: 3.20 mu g/kg/day, 2.5th-97.5th percentiles: 2.35-4.67 mu g/kg/day) than those with normal renal function (1.99, 1.22-3.42 mu g/kg/day). The POD for CKD was 1.557 mu g/kg/day, which could serve as a possible reference value for CKD risk assessment. The MOEs indicated that the CKD risk due to iAs intake may potentially be a cause for high concern for the population with reduced renal function. The iAs-induced urinary cancer risk may be a cause for moderate-to-high concern.
COA
Publication 
1.jpg)
Loading ......
